PD-1, PD-L1 and PD-L2 Expression in Well-Differentiated Small Bowel Gastrointestinal Neuroendocrine Tumours (Wd SB-NETs).

#1680

Introduction: Treatment options for patients with advanced Wd SB-NETs are limited.

Aim(s): We describe immune cell infiltration in this disease group.

Materials and methods: Patients diagnosed with Wd (WHO grade 1-2) SB-NETs, who had provided informed consent for analysis of archival tissue, were eligible. Programmed death-ligand 1 (PD-L1), PD-L2, PD-1 and tumour infiltrating lymphocytes (TILs) were analysed by immunohistochemistry (IHC); PD-L1, PD1 and PD-L2 were also assessed with reverse transcription polymerase chain reaction (RT-PCR).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lamarca A

Authors: Lamarca A, Nonaka D, Breitwieser W, Ashton G, Barriuso J,

Keywords: immunotherapy,